Cargando…

Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control

BACKGROUND: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer (HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG), submandibular (SMG), and accessory salivary glands represented by the oral ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Chajon, Enrique, Lafond, Caroline, Louvel, Guillaume, Castelli, Joël, Williaume, Danièle, Henry, Olivier, Jégoux, Franck, Vauléon, Elodie, Manens, Jean-Pierre, Le Prisé, Elisabeth, de Crevoisier, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680304/
https://www.ncbi.nlm.nih.gov/pubmed/23721062
http://dx.doi.org/10.1186/1748-717X-8-132
_version_ 1782273100328468480
author Chajon, Enrique
Lafond, Caroline
Louvel, Guillaume
Castelli, Joël
Williaume, Danièle
Henry, Olivier
Jégoux, Franck
Vauléon, Elodie
Manens, Jean-Pierre
Le Prisé, Elisabeth
de Crevoisier, Renaud
author_facet Chajon, Enrique
Lafond, Caroline
Louvel, Guillaume
Castelli, Joël
Williaume, Danièle
Henry, Olivier
Jégoux, Franck
Vauléon, Elodie
Manens, Jean-Pierre
Le Prisé, Elisabeth
de Crevoisier, Renaud
author_sort Chajon, Enrique
collection PubMed
description BACKGROUND: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer (HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG), submandibular (SMG), and accessory salivary glands represented by the oral cavity (OC). METHODS: Seventy consecutive patients with Stage I-II (23%) or III/IV (77%) HNC treated by definitive IMRT were included. For all LR failure patients, the FDG-PET and CT scans documenting recurrence were rigidly registered to the initial treatment planning CT. Failure volumes (Vf) were delineated based on clinical, radiological, and histological data. The percentage of Vf covered by 95% of the prescription isodose (Vf-V95) was analyzed. Failures were classified as “in-field” if Vf–V95 ≥ 95%, “marginal” if 20% < Vf-V95 < 95%, and “out-of-field” if Vf-V95 ≤20%. Correlation between Vf-V95 and mean doses (Dmean) in the PG, SMG, and OC was assessed using Spearman’s rank-order correlation test. The salivary gland dose impact on the LR recurrence risk was assessed by Cox analysis. RESULTS: The median follow-up was 20 months (6–35). Contralateral and ipsilateral PGs were spared in 98% and 54% of patients, respectively, and contralateral and ipsilateral SMG in 26% and 7%, respectively. The OC was spared to a dose ≤40 Gy in 26 patients (37%). The 2-year LR control rate was 76.5%. One recurrence was “marginal”, and 12 were “in-field”. No recurrence was observed in vicinity of spared structures. Vf-V95 was not significantly correlated with Dmean in PG, SMG, and OC. The LR recurrence risk was not increased by lower Dmean in the salivary glands, but by T (p = 0.04) and N stages (p = 0.03). CONCLUSION: Over 92% of LR failures occurred “in-field” within the high dose region when using IMRT with a whole salivary gland-sparing strategy. Sparing SMG and OC in addition to PG thus appears a safe strategy.
format Online
Article
Text
id pubmed-3680304
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36803042013-06-13 Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control Chajon, Enrique Lafond, Caroline Louvel, Guillaume Castelli, Joël Williaume, Danièle Henry, Olivier Jégoux, Franck Vauléon, Elodie Manens, Jean-Pierre Le Prisé, Elisabeth de Crevoisier, Renaud Radiat Oncol Research BACKGROUND: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer (HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG), submandibular (SMG), and accessory salivary glands represented by the oral cavity (OC). METHODS: Seventy consecutive patients with Stage I-II (23%) or III/IV (77%) HNC treated by definitive IMRT were included. For all LR failure patients, the FDG-PET and CT scans documenting recurrence were rigidly registered to the initial treatment planning CT. Failure volumes (Vf) were delineated based on clinical, radiological, and histological data. The percentage of Vf covered by 95% of the prescription isodose (Vf-V95) was analyzed. Failures were classified as “in-field” if Vf–V95 ≥ 95%, “marginal” if 20% < Vf-V95 < 95%, and “out-of-field” if Vf-V95 ≤20%. Correlation between Vf-V95 and mean doses (Dmean) in the PG, SMG, and OC was assessed using Spearman’s rank-order correlation test. The salivary gland dose impact on the LR recurrence risk was assessed by Cox analysis. RESULTS: The median follow-up was 20 months (6–35). Contralateral and ipsilateral PGs were spared in 98% and 54% of patients, respectively, and contralateral and ipsilateral SMG in 26% and 7%, respectively. The OC was spared to a dose ≤40 Gy in 26 patients (37%). The 2-year LR control rate was 76.5%. One recurrence was “marginal”, and 12 were “in-field”. No recurrence was observed in vicinity of spared structures. Vf-V95 was not significantly correlated with Dmean in PG, SMG, and OC. The LR recurrence risk was not increased by lower Dmean in the salivary glands, but by T (p = 0.04) and N stages (p = 0.03). CONCLUSION: Over 92% of LR failures occurred “in-field” within the high dose region when using IMRT with a whole salivary gland-sparing strategy. Sparing SMG and OC in addition to PG thus appears a safe strategy. BioMed Central 2013-05-30 /pmc/articles/PMC3680304/ /pubmed/23721062 http://dx.doi.org/10.1186/1748-717X-8-132 Text en Copyright © 2013 Chajon et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Chajon, Enrique
Lafond, Caroline
Louvel, Guillaume
Castelli, Joël
Williaume, Danièle
Henry, Olivier
Jégoux, Franck
Vauléon, Elodie
Manens, Jean-Pierre
Le Prisé, Elisabeth
de Crevoisier, Renaud
Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
title Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
title_full Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
title_fullStr Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
title_full_unstemmed Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
title_short Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
title_sort salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680304/
https://www.ncbi.nlm.nih.gov/pubmed/23721062
http://dx.doi.org/10.1186/1748-717X-8-132
work_keys_str_mv AT chajonenrique salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT lafondcaroline salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT louvelguillaume salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT castellijoel salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT williaumedaniele salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT henryolivier salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT jegouxfranck salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT vauleonelodie salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT manensjeanpierre salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT lepriseelisabeth salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol
AT decrevoisierrenaud salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol